Treatment Patterns, Comorbidities, Healthcare Resource Utilization and Related **Costs of Dermatomyositis and Polymyositis** in the United States: A Cohort Study in the **Merative[™] MarketScan[®] Database**

Caroline Foch¹, Sabrina de Souza¹, Luisa Henkel², **Xiaoxue Chen**³, Deborah Denis³, Jeffrey M. Muir⁴ ¹the healthcare business of Merck KGaA, Darmstadt, Germany; ²Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; ³EMD Serono, Rockland, MA, USA; ⁴Cytel Inc., Toronto, Canada

CONCLUSIONS



Glucocorticoids were the predominate treatment for DM and PM in the United States

These data provide an important update on the treatment landscape and economic burden of DM and PM in the United States



ABBREVIATIONS AM, antimalarials; CI, calcineurin inhibitors; CRG, corticotropin repository gel; DM, dermatomyositis; SD, standard deviation; TNF, tumor necrosis factor. REFERENCES

1. Lundberg IE, et al. Nat Rev Dis Primers. 2021;7(1):86; 2. Barsotti S, et al. Curr Treatm Opt Rheumatol. 2018;4(4):299–315; 3. Bensimon A, et al. Ann Rheum Dis. 2022;81:716–717(POS0848); 4. Aggarwal R, et al. Arthritis Rheumatol. 2021;73(suppl 9):A1039. CF and SdS are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. LH is an employees of EMD Serono. JMM is an employee of Cytel Inc., Toronto, Canada, and has worked as a consultant to EMD Serono. Medical writing support was provided by Bioscript Group, Macclesfield, UK, and supported by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Presented at the ISPOR 2024 meeting | 5–8 May 2024 | Atlanta, GA, USA



GET POSTER PDF Copies of this poster obtained through QR (Quick Response) code are for personal use only and may not be reproduced without written permission of the authors



Overall costs, driven largely by outpatient charges, were higher than previously reported

RESULTS



This study was funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)





	DM Cohort, n (%) n = 3693	PM Cohort, n (%) n = 2841
Hypertension	1633 (44)	1659 (58)
Hyperlipidemia	1448 (39)	1416 (50)
Respiratory infection	1433 (39)	1087 (38)
Vitamin D deficiency	1161 (31)	934 (33)
Obesity	1049 (28)	984 (35)
Gastro-esophageal reflux disease	1047 (28)	913 (32)